(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.49%) $78.49
(0.70%) $2.16
(0.60%) $2 322.50
(1.85%) $27.18
(-0.34%) $962.00
(-0.02%) $0.929
(-0.21%) $10.85
(-0.04%) $0.797
(0.00%) $91.45
Quarter results tomorrow
(bmo 2024-05-07)
Expected move: +/- 9.64%
@ $26.76
Issued: 14 Feb 2024 @ 12:06
Return: -47.91%
Previous signal: Feb 14 - 09:30
Previous signal:
Return: 6.23 %
Live Chart Being Loaded With Signals
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults...
Stats | |
---|---|
Today's Volume | 895 697 |
Average Volume | 1.07M |
Market Cap | 838.94M |
EPS | $0 ( 2024-04-25 ) |
Next earnings date | ( $-1.590 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.660 |
ATR14 | $0.0160 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-13 | Greene Barry E | Buy | 168 000 | Stock Option (Right to Buy) |
2024-02-13 | Cook Anne Marie | Buy | 11 250 | Common Stock |
2024-02-13 | Cook Anne Marie | Buy | 22 500 | Stock Option (Right to Buy) |
2024-02-13 | Gault Laura | Buy | 22 500 | Stock Option (Right to Buy) |
2024-02-13 | Gault Laura | Buy | 11 250 | Common Stock |
INSIDER POWER |
---|
92.81 |
Last 97 transactions |
Buy: 1 228 960 | Sell: 86 892 |
Volume Correlation
SAGE Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
FXNC | 0.945 |
OBNK | 0.93 |
SFST | 0.925 |
WKME | 0.925 |
WNEB | 0.923 |
SIRI | 0.917 |
TRVN | 0.916 |
RCMT | 0.915 |
TACT | 0.915 |
LCFY | 0.914 |
10 Most Negative Correlations | |
---|---|
PWP | -0.922 |
FTII | -0.918 |
XOG | -0.918 |
TRMR | -0.911 |
COMT | -0.907 |
KNTK | -0.906 |
IXAQ | -0.905 |
BRY | -0.905 |
FTXN | -0.895 |
STAA | -0.893 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
SAGE Therapeutics Inc Correlation - Currency/Commodity
SAGE Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $86.46M |
Gross Profit: | $84.30M (97.50 %) |
EPS: | $-9.05 |
FY | 2023 |
Revenue: | $86.46M |
Gross Profit: | $84.30M (97.50 %) |
EPS: | $-9.05 |
FY | 2022 |
Revenue: | $7.69M |
Gross Profit: | $6.87M (89.42 %) |
EPS: | $-8.49 |
FY | 2021 |
Revenue: | $6.31M |
Gross Profit: | $5.76M (91.23 %) |
EPS: | $-7.80 |
Financial Reports:
No articles found.
SAGE Therapeutics Inc
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators